drugset / Trial / NCT05685615
PK of BV100 in Patients VABP Suspected or Confirmed to Be Due to CRAB
RandomizedParallel-groupOpen-labelTreatment
Summary
A multicenter Phase 2 study to evaluate the pharmacokinetics, efficacy, and safety of intravenous BV100 combined with Polymyxin B in adult patients with VABP suspected or confirmed to be due to CRAB
Timeline
- Start
- 2023-04-20
- Primary completion
- 2024-11-01
- Completion
- 2024-12-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Rifabutin | Small molecule | 200 mg | Intravenous |
| Subject | Rifabutin | Small molecule | 300 mg | Intravenous |
| Background | Polymyxin B | Peptide | 12500 iu/kg | Intravenous |
| Background | Polymyxin B | Peptide | 15000 iu/kg | Intravenous |
Indications
No indication recorded.